IMS Company Profiles - Report Buyer

IMS COM PANY PRO FILES NOVARTIS
Mergers & Acquisitions
• Year: 2008
Major Events
De cem ber: Novartis ac quired the pul mo nary drug de liv ery unit of Nektar (USA). It has ac quired spe cific
pul mo nary de liv ery as sets, tech nol ogy, and in tel lec tual prop erty from Nektar for $115 mil lion in cash.
Cer tain dry pow der and liq uid pul mo nary for mu la tion and man u fac tur ing as sets (in clud ing cap i tal equip -
ment and man u fac tur ing cap i tal lease ob li ga tions) will be ac quired by Novartis. Novartis will also take on
140 Nektar per son nel, as well as cer tain in tel lec tual prop erty and man u fac tur ing meth ods. Man u fac tur -
ing and roy alty rights to tobramycin inhaled powder (Inhaled Tobi) will be transferred to Novartis.
July: Novartis took a 25% stake in the US oph thal mol ogy com pany Alcon, which is ma jor ity-owned by
Nes tle (Swit zer land), for $10.4 bil lion. Novartis also gained rights to ac quire the re main ing 52% Alcon
stake held by Nes tle be tween Jan u ary 2010 and Jul 2011 for up to ap prox i mately $28 billion.
Novartis be came the ma jor ity owner of Speedel Hold ings Ltd (Swit zer land), fol low ing the ac qui si tion of
an ad di tional 51.7% stake. A man da tory pub lic ten der of fer be gan in Au gust 2008 to buy the re main ing
shares in the com pany. Novartis states that to tal ac qui si tion costs are es ti mated at around $880 mil lion.
Novartis has a long-stand ing col lab o ra tion with Speedel and states that Speedel’s R&D pipe line is a
strong fit with its lead ing position in cardiovascular disease.
June: Novartis signed a de fin i tive agree ment to ac quire Protez Pharmaceuticals (USA), along with the
rights in North Amer ica and Eu rope to PZ 601, a novel hos pi tal an ti bi otic in clin i cal development.
Jan u ary: It was re ported that Novartis is to close its Tsukuba re search cen ter in Ja pan.
• Year: 2006
Novartis ac quired the an i mal health busi ness of Sankyo Lifetech, a sub sid iary of Sankyo, ex pand ing the
pres ence of Novartis An i mal Health busi ness in Japan.
Novartis made a $569 mil lion of fer for NeuTec Pharma, a Brit ish de vel oper of anti-in fec tion drugs. With
this move, Novartis in tends to ex pand its in fec tious dis ease port fo lio and strengthen its po si tion in hos pi -
tal infections.
Ac qui si tion of Chiron was com pleted af ter Novartis had raised its of fer for a third time to please some
Chiron’s share hold ers who threat ened to vote against the deal. The fi nal price was $48 per share.
• Year: 2005
Novartis an nounced that it had en tered into a de fin i tive merger agree ment with Chiron. It will ac quire all
of the re main ing shares of Chiron that it does not al ready own for $45 per share.
Novartis bought a 19.9% stake in Alnylam, a US leader in RNA in ter fer ence (RNAi) re search, for $56.8
mil lion. The pay ment, un der pin ning a broader col lab o ra tion be tween the two com pa nies, is part of a
com plex deal which could see RNAi tech nol ogy even tu ally in cor po rated into Novartis’ own
pharmaceuticals R&D.
© 2009 IMS Health In cor po rated or its af fil i ates Page 138